Copyright Reports & Markets. All rights reserved.

(Post-pandemic Era)-Global The Influenza (Flu) Antiviral Drugs Market Segment Research Report 2021

Request for Sample of this report
Buy now

Table of Contents

    Global The Influenza (Flu) Antiviral Drugs Market Segment Research Report 2021

      1. Research Scope

        2. Market Overview

        • 2.1 Product Introduction, Application, Picture
        • 2.2 Global The Influenza (Flu) Antiviral Drugs Market by Value
          • 2.2.1 Global The Influenza (Flu) Antiviral Drugs Revenue by Type
          • 2.2.2 Global The Influenza (Flu) Antiviral Drugs Market by Value (%)
        • 2.3 Global The Influenza (Flu) Antiviral Drugs Market by Production
          • 2.3.1 Global The Influenza (Flu) Antiviral Drugs Production by Type
          • 2.3.2 Global The Influenza (Flu) Antiviral Drugs Market by Production (%)

        3. The Major Driver of The Influenza (Flu) Antiviral Drugs Industry

        • 3.1 Historical & Forecast Global The Influenza (Flu) Antiviral Drugs Demand
        • 3.2 Largest Application for The Influenza (Flu) Antiviral Drugs (2017-2027)
        • 3.3 The Major Downstream Company in China Market 2021

        4. Global and Regional The Influenza (Flu) Antiviral Drugs Market

        • 4.1 Regional Market Size in Terms of Production & Demand (2021)
        • 4.2 Regional Market Share in Terms of Revenue (2019-2027)
        • 4.3 Concentration Ratio (CR5& CR10) of The Influenza (Flu) Antiviral Drugs Market
        • 4.4 Mergers & Acquisitions, Expansion Plans

        5. US The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)

        • 5.1 Current and Estimated Production Breakdown by Type
        • 5.2 Current and Estimated Demand Breakdown by Type
        • 5.3 Current and Estimated Demand Breakdown by Application
        • 5.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
        • 5.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

        6. Europe The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)

        • 6.1 Current and Estimated Production Breakdown by Type
        • 6.2 Current and Estimated Demand Breakdown by Type
        • 6.3 Current and Estimated Demand Breakdown by Application
        • 6.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
        • 6.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

        7. China The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)

        • 7.1 Current and Estimated Production Breakdown by Type
        • 7.2 Current and Estimated Demand Breakdown by Type
        • 7.3 Current and Estimated Demand Breakdown by Application
        • 7.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
        • 7.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

        8. Japan The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)

        • 8.1 Current and Estimated Production Breakdown by Type
        • 8.2 Current and Estimated Demand Breakdown by Type
        • 8.3 Current and Estimated Demand Breakdown by Application
        • 8.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
        • 8.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

        9. India The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)

        • 9.1 Current and Estimated Production Breakdown by Type
        • 9.2 Current and Estimated Demand Breakdown by Type
        • 9.3 Current and Estimated Demand Breakdown by Application
        • 9.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
        • 9.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

        10. Korea The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)

        • 10.1 Current and Estimated Production Breakdown by Type
        • 10.2 Current and Estimated Demand Breakdown by Type
        • 10.3 Current and Estimated Demand Breakdown by Application
        • 10.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
        • 10.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

        11. Southeast Asia The Influenza (Flu) Antiviral Drugs Production, Demand (2017-2027)

        • 11.1 Current and Estimated Production Breakdown by Type
        • 11.2 Current and Estimated Demand Breakdown by Type
        • 11.3 Current and Estimated Demand Breakdown by Application
        • 11.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
        • 11.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

        12. Global The Influenza (Flu) Antiviral Drugs Average Price Trend

        • 12.1 Market Price for Each Type of The Influenza (Flu) Antiviral Drugs in US (2017-2021)
        • 12.2 Market Price for Each Type of The Influenza (Flu) Antiviral Drugs in Europe (2017-2021)
        • 12.3 Market Price for Each Type of The Influenza (Flu) Antiviral Drugs in China (2017-2021)
        • 12.4 Market Price for Each Type of The Influenza (Flu) Antiviral Drugs in Japan (2017-2021)
        • 12.5 Market Price for Each Type of The Influenza (Flu) Antiviral Drugs in India (2017-2021)
        • 12.6 Market Price for Each Type of The Influenza (Flu) Antiviral Drugs in Korea (2017-2021)
        • 12.7 Market Price for Each Type of The Influenza (Flu) Antiviral Drugs in Southeast Asia (2017-2021)

        13. Industrial Chain (Impact of COVID-19)

        • 13.1 The Influenza (Flu) Antiviral Drugs Industrial Chain Analysis
        • 13.2 Downstream
        • 13.3 Impact of COVID-19
        • 13.4 Technology Trends of The Influenza (Flu) Antiviral Drugs

        14. The Influenza (Flu) Antiviral Drugs Competitive Landscape

        • 14.1 Pfizer
          • 14.1.1 Pfizer Company Profiles
          • 14.1.2 Pfizer Product Introduction
          • 14.1.3 Pfizer The Influenza (Flu) Antiviral Drugs Sales, Revenue (2017-2021)
          • 14.1.4 Strategic initiatives
        • 14.2 Gilead Sciences
          • 14.2.1 Gilead Sciences Company Profiles
          • 14.2.2 Gilead Sciences Product Introduction
          • 14.2.3 Gilead Sciences The Influenza (Flu) Antiviral Drugs Sales, Revenue (2017-2021)
          • 14.2.4 Strategic initiatives
        • 14.3 Johnson & Johnson
          • 14.3.1 Johnson & Johnson Company Profiles
          • 14.3.2 Johnson & Johnson Product Introduction
          • 14.3.3 Johnson & Johnson The Influenza (Flu) Antiviral Drugs Sales, Revenue (2017-2021)
          • 14.3.4 Strategic initiatives
        • 14.4 Roche
          • 14.4.1 Roche Company Profiles
          • 14.4.2 Roche Product Introduction
          • 14.4.3 Roche The Influenza (Flu) Antiviral Drugs Sales, Revenue (2017-2021)
          • 14.4.4 Strategic initiatives
        • 14.5 AbbVie
          • 14.5.1 AbbVie Company Profiles
          • 14.5.2 AbbVie Product Introduction
          • 14.5.3 AbbVie The Influenza (Flu) Antiviral Drugs Sales, Revenue (2017-2021)
          • 14.5.4 Strategic initiatives
        • 14.6 Sanofi
          • 14.6.1 Sanofi Company Profiles
          • 14.6.2 Sanofi Product Introduction
          • 14.6.3 Sanofi The Influenza (Flu) Antiviral Drugs Sales, Revenue (2017-2021)
          • 14.6.4 Strategic initiatives
        • 14.7 Amgen
          • 14.7.1 Amgen Company Profiles
          • 14.7.2 Amgen Product Introduction
          • 14.7.3 Amgen The Influenza (Flu) Antiviral Drugs Sales, Revenue (2017-2021)
          • 14.7.4 Strategic initiatives
        • 14.8 Novartis
          • 14.8.1 Novartis Company Profiles
          • 14.8.2 Novartis Product Introduction
          • 14.8.3 Novartis The Influenza (Flu) Antiviral Drugs Sales, Revenue (2017-2021)
          • 14.8.4 Strategic initiatives
        • 14.9 Merck & Co. (MSD)
          • 14.9.1 Merck & Co. (MSD) Company Profiles
          • 14.9.2 Merck & Co. (MSD) Product Introduction
          • 14.9.3 Merck & Co. (MSD) The Influenza (Flu) Antiviral Drugs Sales, Revenue (2017-2021)
          • 14.9.4 Strategic initiatives
        • 14.10 GlaxoSmithKline (GSK)
          • 14.10.1 GlaxoSmithKline (GSK) Company Profiles
          • 14.10.2 GlaxoSmithKline (GSK) Product Introduction
          • 14.10.3 GlaxoSmithKline (GSK) The Influenza (Flu) Antiviral Drugs Sales, Revenue (2017-2021)
          • 14.10.4 Strategic initiatives
        • 14.11 Bayer
        • 14.12 Takeda
        • 14.13 AstraZeneca
        • 14.14 Novo Nordisk
        • 14.15 Teva
        • 14.16 Bristol-Myers Squibb
        • 14.17 Boehringer Ingelheim
        • 14.18 Allergan
        • 14.19 Eli Lilly

        15. Conclusion

        Summary

        The global economy is expected to expand 5.6% in 2021，global recovery is strong but uneven as many emerging market and developing economies continue to struggle with the COVID-19 pandemic, the world is unlikely to ever reach global herd immunity. However, the recovery in many countries is being held back by a resurgence of COVID-19 cases and lagging vaccination progress, as well as the withdrawal of policy support in some instances.

        The annual U.S. economic growth rate slipped to -3.5% in 2020, but grew at a yearly pace of more than 6% in the previous two quarters of 2021. The economy of continental Europe bounced back in the second quarter after having contracted in both the fourth quarter of 2020 and the first quarter of 2021, as the vaccinations accelerated, and governments eased restrictions. Among major economies, the annualized growth rate was 6.1% in Germany, 3.6% in France, 11.2% in Italy, and 11.7% in Spain. The especially rapid growth in Spain and Italy was attributed to a surge in consumer spending, likely the result of an easing of economic restrictions.

        Regional Economic Prospects: Growth in the East Asia and Pacific is projected to accelerate by 7.7% in 2021, Central Asia is forecast to grow by 3.9% this year, economic activity in the Middle East and North Africa is forecast to advance by 2.4%, South Asia is projected to expand by 6.8%.

        The global The Influenza (Flu) Antiviral Drugs market size was USD XX billion in 2021. It is likely to progress at a CAGR of XX% during the forecast period of 2022-2027, according to XYZResearch analysis, The segment in The Influenza (Flu) Antiviral Drugs market is estimated to reach a market value of USD XX billion by 2021 from an initial market value of USD XX billion in 2021. China market value in 2021 is about USD XX billion, and China The Influenza (Flu) Antiviral Drugs production is XX (K Units). US market value in 2021 is about USD XX billion, and US The Influenza (Flu) Antiviral Drugs production is XX (K Units). Europe market value in 2021 is about USD XX billion, and Europe The Influenza (Flu) Antiviral Drugs production is XX (K Units).

        Regional Segmentation (Value; Revenue, USD Million, 2017 - 2027) of The Influenza (Flu) Antiviral Drugs Market by XYZResearch Include
        USA
        Europe
        China
        Japan
        India
        Korea
        Southeast Asia
        Competitive Analysis; Who are the Major Players in The Influenza (Flu) Antiviral Drugs Market?
        Pfizer
        Gilead Sciences
        Johnson & Johnson
        Roche
        AbbVie
        Sanofi
        Amgen
        Novartis
        Merck & Co. (MSD)
        GlaxoSmithKline (GSK)
        Bayer
        Takeda
        AstraZeneca
        Novo Nordisk
        Teva
        Bristol-Myers Squibb
        Boehringer Ingelheim
        Allergan
        Eli Lilly
        Major Type of The Influenza (Flu) Antiviral Drugs Covered in XYZResearch report:
        Penetration and Dehulling Inhibitors
        DNA Polymerase Inhibitors
        Reverse Transcriptase Inhibitors
        Protein Inhibitors
        Neuraminidase Inhibitors
        Broad-spectrum Antiviral Drugs
        Application Segments Covered in XYZResearch Market
        Hospital
        Clinic
        Household
        Others

        For any other requirements, please feel free to contact us and we will provide you customized report.
        Buy now